Physician profile
David A Altman
NPI 1205831005
$1,884,460.92
in general payments reported to CMS, 2019-2025
39 companies · $358K in 2025
The $358K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218K · 2020: $118K · 2021: $108K · 2022: $222K · 2023: $395K · 2024: $465K · 2025: $358K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900K · Consulting Fee: $169K · Travel and Lodging: $100K · Food and Beverage: $35K · Honoraria: $14K · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900,424.90 |
| Consulting Fee | $169,282.78 |
| Travel and Lodging | $99,607.07 |
| Food and Beverage | $34,875.85 |
| Honoraria | $13,860.08 |
| Education | $408.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $330,667.43 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $188,847.21 | 2023-2025 | Zoryve |
| Abbvie INC. | $171,949.32 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $156,208.03 | 2019-2025 | |
| Lilly USA, LLC | $131,446.63 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $123,120.55 | 2019-2025 | Dupixent, Libtayo |
| Celgene Corporation | $119,315.90 | 2019 | |
| Janssen Biotech, INC. | $117,065.79 | 2019-2025 | Tremfya |
| Incyte Corporation | $113,016.30 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $72,802.31 | 2019-2025 | |
| Dermavant Sciences, INC. | $64,024.65 | 2022-2024 | Vtama |
| Ucb, INC. | $57,811.08 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $51,139.85 | 2019-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $49,642.54 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26,286.07 | 2019-2025 | Cabtreo, Arazlo, Jublia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.